The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer

INTRODUCTION: Bladder cancer (BLCA) is a highly malignant tumor of the urinary system, but the prognosis and survival rates have little improvement based on current therapeutic strategy. Immune checkpoint inhibitors (ICIs) therapy revolutionized the treatment of BLCA, but the clinical application of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zihan, Liu, Siyang, Sun, Rui, Zhu, Wenjie, Zhang, Yulin, Liu, Tianyao, Li, Tianhang, Jiang, Ning, Guo, Hongqian, Yang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027707/
https://www.ncbi.nlm.nih.gov/pubmed/36960067
http://dx.doi.org/10.3389/fimmu.2023.1085476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027707/
https://www.ncbi.nlm.nih.gov/pubmed/36960067
http://dx.doi.org/10.3389/fimmu.2023.1085476

Ejemplares similares